Loading company…
Otovia develops gene therapies for hearing loss and auditory disorders.
Otovia develops gene replacement therapies for hearing loss, using a dual AAV delivery platform targeting genetic conditions linked to GJB2 and OTOF gene defects. The company is conducting multi-center Investigator-Initiated Trials for its OTOF pipeline. Founded in 2022 and based in Shanghai, China, it raised approximately CNY 100 million from Dingxin Capital and Nanjing Innovation Capital Group in January 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in